27 Mar 2017 | Fujirebio Europe launches the Lumipulse® G hs Troponin I and Lumipulse G Myoglobin immunoassays for both the LUMIPULSE G1200 and G600II platforms

Gent, Belgium: March 27 2017 - Fujirebio Europe has announced the release of the Lumipulse G hs Troponin I assay for use in the diagnosis of Acute Myocardial Infarction (AMI). In addition, the company also launches its Lumipulse G Myoglobin assay, both assays providing precise and sensitive results in 35 minutes.

“It is a well-known fact that consistent assay performance is crucial for clinicians facing the difficult diagnosis of AMI.” said Christiaan De Wilde, CEO of Fujirebio Europe. “The LUMIPULSE G platforms have proven to be both robust and reliable, and our cardiac assays provide high sensitivity, high precision and a wide dynamic range. These are key factors that ensure you get the right result when time is limited. Furthermore, our unique single test cartridge concept helps to eliminate reagent waste for cardiac markers such as CK-MB and Myoglobin that can be run in lower volumes.”

In April 2016, Fujirebio Europe launched the first of its cardiac biomarker assays, the Lumipulse G BNP assay for the quantitative measurement of brain natriuretic peptide (BNP) in EDTA plasma.

 
About Troponin

The Troponin complex plays an important role in the regulation of skeletal and cardiac muscle contraction. In humans, Troponin I (TnI) and Troponin T (TnT) are presented by three isoforms each:

  • Two isoforms of both TnI and TnT (skTnI and skTnT) are expressed in skeletal muscles.

  • The third isoform of both TnI and TnT (cTnI and cTnT) is typical for cardiac muscle.

Cardiac troponins have become the biomarker of choice to aid in the diagnosis of AMI and today, high sensitivity assays are recommended by the European Society of Cardiology*.

* 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

  

About Fujirebio

Fujirebio is a global leader in the field of high quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.  

Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. 

Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.  

Fujirebio is today a member of Miraca Group (Miraca Holdings Inc. listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1.200 people in Asia, Europe and America.

For more information about Fujirebio please visit www.fujirebio-europe.com. 

CLOSE

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.